Lantheus Holdings Inc (LNTH) Director Sells $126,300.00 in Stock

Lantheus Holdings Inc (NASDAQ:LNTH) Director Brian A. Markison sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $25.26, for a total transaction of $126,300.00. Following the sale, the director now directly owns 92,467 shares in the company, valued at $2,335,716.42. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

NASDAQ:LNTH opened at $24.15 on Friday. The company has a debt-to-equity ratio of 3.71, a quick ratio of 3.08 and a current ratio of 3.70. Lantheus Holdings Inc has a 52 week low of $12.59 and a 52 week high of $26.30. The firm has a market capitalization of $930.93 million, a PE ratio of 25.16, a PEG ratio of 1.74 and a beta of 1.59.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, February 19th. The medical equipment provider reported $0.24 EPS for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.09. Lantheus had a net margin of 11.80% and a return on equity of 73.07%. The company had revenue of $86.27 million for the quarter, compared to analyst estimates of $83.93 million. During the same period in the prior year, the firm posted $2.47 EPS. The company’s quarterly revenue was up 6.2% on a year-over-year basis. Equities research analysts forecast that Lantheus Holdings Inc will post 1.15 earnings per share for the current year.

Large investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its stake in shares of Lantheus by 51.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 575 shares during the last quarter. Financial Gravity Companies Inc. bought a new stake in shares of Lantheus in the 4th quarter valued at $45,000. Advisor Group Inc. boosted its stake in shares of Lantheus by 1,837.2% in the 4th quarter. Advisor Group Inc. now owns 4,378 shares of the medical equipment provider’s stock valued at $69,000 after purchasing an additional 4,152 shares during the last quarter. Meeder Asset Management Inc. boosted its stake in shares of Lantheus by 212.8% in the 1st quarter. Meeder Asset Management Inc. now owns 4,757 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 3,236 shares during the last quarter. Finally, Nkcfo LLC bought a new stake in shares of Lantheus in the 1st quarter valued at $206,000. 93.34% of the stock is currently owned by institutional investors.

A number of research firms have weighed in on LNTH. BidaskClub lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Thursday. Zacks Investment Research raised shares of Lantheus from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a report on Tuesday, April 16th. TheStreet raised shares of Lantheus from a “c+” rating to a “b” rating in a report on Monday, March 4th. Finally, ValuEngine raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Lantheus has an average rating of “Buy” and a consensus price target of $23.33.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/lantheus-holdings-inc-lnth-director-sells-126300-00-in-stock.html.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Article: What is a Swap?

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.